Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blinded, Comparative Clinical Trial for a Group B Streptococcus Serotype III-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Acquisition of GBS Type III

NCT00128219 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00128219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blinded, Comparative Clinical Trial for a Group B Streptococcus Serotype III-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Acquisition of GBS Type III
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2003
Completion date
December 31, 2008
Enrollment
667 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

beta haemolytic streptococcal infection